Conference Coverage

Which Probiotics Are Effective in Irritable Bowel Syndrome?


 

In a murine model, but not in humans, some strains, especially L acidophilus NCFM, have shown an antinociceptive effect by inducing opioid and cannabinoid receptors.

Only in animals to date, L farciminis and B lactis CNCM I-2494 have shown prevention of induced hypersensitivity (ie, inhibition of the cytoskeleton contraction of colon epithelial cells and subsequent opening of tight junctions).

B infantis 35624 has an anti-inflammatory action by modifying the IL-10 and IL-12 cytokine ratio in animals and humans. It has an immunomodulatory action by increasing dendritic cells in the mucosa and decreasing Th1 and Th7 helper T cells.

B infantis 35624 and L farciminis are two strains that decrease visceral sensitivity in mice.

Escherichia coli Nissle 1917 acts on lipopeptide production with an antinociceptive effect, as observed in mice, by decreasing visceral sensitivity through calcium nociceptor flux blockade (action on GABA type B receptor).

Acting on dysbiosis by modifying fecal microbiota during probiotic intake is possible but depends on the probiotics, like B infantis 35624. In humans, B longum NCC 3001 could modify brain activations.

Dr. Sabaté disclosed financial relationships with Mayoly Spindler, Kyowa Kirin, Tillotts, Servier, Norgine, Biocodex, Merck, Viatris, Abivax, and Inventiva.

This story was translated from the Medscape French edition using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. A version of this article appeared on Medscape.com.

Pages

Recommended Reading

New Quality Measure Improves Follow-Up for CRC Screening
MDedge Internal Medicine
Poop Doesn’t Lie: What Fecal ‘Forensics’ Tells Us About Diet
MDedge Internal Medicine
Ultraprocessed Food May Increase Long-Term Risk for IBS
MDedge Internal Medicine
Liquid Biopsy Has Near-Perfect Accuracy for Early Pancreatic Cancer
MDedge Internal Medicine
A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her Trunk and Extremities
MDedge Internal Medicine
What to Know About the Next-Gen FIT for CRC Screening
MDedge Internal Medicine
Further Support for CRC Screening to Start at Age 45: Meta-Analysis
MDedge Internal Medicine
Blood Test Shows Promise for Improving CRC Screening
MDedge Internal Medicine
Sugar Substitutes Satisfy Appetite, Blunt Insulin Response
MDedge Internal Medicine
Second Ustekinumab Biosimilar Gets FDA Approval
MDedge Internal Medicine